Numerous clinical trials have investigated COX-2 as a molecular target for CRC therapy in terms of the introduction of non-steroidal anti-inflammatory drugs into standard therapeutic protocols and also as a potent chemopreventive agent in the high-risk population [129]. This evidence concerns the gene PTGS2 and colorectal carcinoma.